Vancocin Generic In Vivo Testing Waiver Is Not Scientifically Sound, ViroPharma Says
This article was originally published in The Pink Sheet Daily
Executive Summary
More stringent testing is needed because the product treats two potentially life-threatening diseases, the firm argues in a supplement to its Petition for Stay of Action.